secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2025-10-06T23:59:59+00:00
Accession:  0001104659-25-097153
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics reports positive Phase 1b data for GT-02287 in Parkinson's disease
--------------------------------------------------------------------------------

- GT-02287 safe and well-tolerated after 90 days; no serious adverse events.
- Transient liver enzyme increases normalized with ongoing dosing.
- Mean UPDRS Part II and III scores improved at Day 90, suggesting disease-slowing effect.
- Plasma PK consistent across 14 participants, within therapeutic range.
- DMC recommended continuation; Australian authorities approved 12-month extension.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925097153/0001104659-25-097153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925097153/tm2528094d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-097153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer